Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis
- 28 January 2011
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 104 (2), 545-551
- https://doi.org/10.1007/s11060-010-0512-2
Abstract
The development of better diagnostic tools and therapeutic modalities has increased the incidence of central nervous system (CNS) metastasis in malignant tumor patients. Hydrocephalus can result from CNS metastasis and frustrate cancer treatment. The authors sought to investigate the outcomes and the roles of ventriculoperitoneal shunts (VPS) in patients with CNS metastasis. The medical records of 50 consecutive patients who underwent VPS for hydrocephalus related to CNS metastasis were analyzed retrospectively. Data included features of primary malignancies, CNS involvement, clinical course and surgical outcome. Median patient age was 55.0 years (range 25–77), and 30 female and 20 male patients were included in the study. At the time of VPS, 10 patients had parenchymal metastases only and 40 patients had leptomeningeal seeding (LMS). Symptom improvement was observed postoperatively in 40 patients (80%), mean Karnofsky performance status (KPS) scale change was from 37.8 to 46.0, and median survival from VPS was 3.0 months (2 days to 54 months). A ventricular opening pressure of >30 cmH2O (HR 6.44, 95% CI 1.26–32.9, P = 0.02) and further cancer treatment after VPS (HR 0.17, 95% CI 0.07–0.42, P < 0.0001) were found to be independent risk factors of poorer and better survival, respectively. Hydrocephalus in CNS metastasis requiring VPS is commonly associated with LMS. VPS is an effective palliative measure and an adequate cancer treatment after VPS may provide the best means of improving survival.Keywords
This publication has 22 references indexed in Scilit:
- Treatment Modalities for Leptomeningeal MetastasesSeminars in Oncology, 2009
- Gliomatosis peritonei associated with a ventriculo-peritoneal shuntClinical Radiology, 2009
- Treatment of central nervous system metastases: parenchymal, epidural, and leptomeningealCurrent Opinion in Oncology, 2006
- Systemic high-dose intravenous methotrexate for central nervous system metastasesJournal of Neuro-Oncology, 2005
- Management of leptomeningeal malignancyExpert Opinion on Pharmacotherapy, 2005
- Ventriculoperitoneal shunt in patients with leptomeningeal metastasisNeurology, 2005
- Leptomeningeal MetastasisCancer Investigation, 2005
- Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabineBritish Journal of Cancer, 2001
- Seven years of clinical experience with the programmable Codman Hakim valve: a retrospective study of 583 patientsJournal of Neurosurgery, 2000
- The risks of metastases from shunting in children with primary central nervous system tumorsJournal of Neurosurgery, 1991